Clinical Trial Update: First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigates autologous stem cell transplantation guided by minimal residual disease markers in newly diagnosed multiple myeloma patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-06-28